Bifogade filer
Kurs
+2,27%
Likviditet
2,98 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-11 | 08:00 | Bokslutskommuniké 2025 |
2025-11-03 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-15 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-13 | N/A | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2025-05-12 | N/A | Årsstämma |
2025-05-02 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-11 | - | Bokslutskommuniké 2024 |
2024-11-01 | - | Kvartalsrapport 2024-Q3 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-26 | - | Årsstämma |
2024-04-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2024-04-15 | - | Kvartalsrapport 2024-Q1 |
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2023-05-11 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2023-02-15 | - | Extra Bolagsstämma 2022 |
2022-11-30 | - | Kvartalsrapport 2022-Q3 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2022-05-11 | - | Årsstämma |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-30 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-31 | - | Kvartalsrapport 2021-Q1 |
2021-04-16 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2021-04-15 | - | Årsstämma |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-27 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-07-01 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2020-06-30 | - | Årsstämma |
2020-05-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-30 | - | Kvartalsrapport 2019-Q2 |
2019-06-17 | - | Årsstämma |
2019-04-08 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-27 | - | Kvartalsrapport 2018-Q2 |
2018-07-25 | - | Extra Bolagsstämma 2018 |
2018-05-09 | - | Kvartalsrapport 2018-Q1 |
2018-04-19 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2018-04-18 | - | Årsstämma |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-11-23 | - | Kvartalsrapport 2017-Q3 |
2017-08-10 | - | Kvartalsrapport 2017-Q2 |
2017-06-29 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
2017-04-24 | - | Extra Bolagsstämma 2017 |
2017-04-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2017-02-14 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | Årsstämma |
2016-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2016-01-28 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-04-28 | - | Kvartalsrapport 2015-Q1 |
2015-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2015-03-26 | - | Årsstämma |
2015-01-27 | - | Bokslutskommuniké 2014 |
2014-10-20 | - | Kvartalsrapport 2014-Q3 |
2014-08-19 | - | Kvartalsrapport 2014-Q2 |
2014-06-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
2014-06-25 | - | Årsstämma |
2014-04-14 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
BrainCool AB reports that the American Medical Association (AMA) have announced the approval of a new Current Procedural Terminology (CPT®) code for reduction of complications associated with oral mucositis in patients undergoing chemotherapy, thereby creating a clear path for reimbursement of the Cooral® System.
The new CPT code, an action resulted from the AMA CPT Editorial Panel’s September 21st - 23rd 2023 meeting, will become effective for use in 2024, and establishing a pathway for widespread adoption and reimbursement. Worth highlighting is that the code application was included by the CPT Committee as a ‘consent’ application. Meaning the application was approved without further discussions and a vote.
CEO Martin Waleij comments
-” This is a major milestone for Cooral® System, and most of all for patients suffering from oral mucositis as a result from cancer treatment. It further recognizes BrainCool’s innovative technology of Cooral® System, with the creation of a new unique procedure category”.
Contacts
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.